BR112022020821A2 - Pirfenidona para tratamento de coronavírus - Google Patents

Pirfenidona para tratamento de coronavírus

Info

Publication number
BR112022020821A2
BR112022020821A2 BR112022020821A BR112022020821A BR112022020821A2 BR 112022020821 A2 BR112022020821 A2 BR 112022020821A2 BR 112022020821 A BR112022020821 A BR 112022020821A BR 112022020821 A BR112022020821 A BR 112022020821A BR 112022020821 A2 BR112022020821 A2 BR 112022020821A2
Authority
BR
Brazil
Prior art keywords
pirfenidone
virus
coronavirus
individual
treatment
Prior art date
Application number
BR112022020821A
Other languages
English (en)
Portuguese (pt)
Inventor
Aguilar-Cordova Estuardo
Aguilar Laura
Agustin Rogelio Magaña Castro José
Original Assignee
Excalibur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excalibur Pharmaceuticals Inc filed Critical Excalibur Pharmaceuticals Inc
Publication of BR112022020821A2 publication Critical patent/BR112022020821A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
BR112022020821A 2020-04-14 2021-04-14 Pirfenidona para tratamento de coronavírus BR112022020821A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (1)

Publication Number Publication Date
BR112022020821A2 true BR112022020821A2 (pt) 2022-12-20

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020821A BR112022020821A2 (pt) 2020-04-14 2021-04-14 Pirfenidona para tratamento de coronavírus

Country Status (14)

Country Link
US (1) US20230117397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135671A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521887A (cg-RX-API-DMAC7.html)
KR (1) KR20230038644A (cg-RX-API-DMAC7.html)
CN (1) CN115916162A (cg-RX-API-DMAC7.html)
AU (1) AU2021254765A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020821A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175526A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002843A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022016155A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22087664A (cg-RX-API-DMAC7.html)
IL (1) IL297296A (cg-RX-API-DMAC7.html)
MX (1) MX2022012986A (cg-RX-API-DMAC7.html)
WO (1) WO2021211745A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030103941A1 (en) * 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AP2007004244A0 (en) * 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
JP7066321B2 (ja) * 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Also Published As

Publication number Publication date
CL2022002843A1 (es) 2023-09-01
CN115916162A (zh) 2023-04-04
MX2022012986A (es) 2023-03-21
EP4135671A1 (en) 2023-02-22
ECSP22087664A (es) 2022-12-30
IL297296A (en) 2022-12-01
KR20230038644A (ko) 2023-03-21
EP4135671A4 (en) 2024-08-14
US20230117397A1 (en) 2023-04-20
WO2021211745A1 (en) 2021-10-21
CA3175526A1 (en) 2021-10-21
AU2021254765A1 (en) 2022-12-08
CO2022016155A2 (es) 2022-12-20
JP2023521887A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2022012986A (es) Pirfenidona para el tratamiento del coronavirus.
Malakar et al. Drug repurposing of quinine as antiviral against dengue virus infection
Borges et al. Chloroquine use improves dengue-related symptoms
CN112778310A8 (zh) 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
Ding et al. Hesperidin attenuates influenza A virus (H1N1) induced lung injury in rats through its anti-inflammatory effect
WO2017044507A3 (en) Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
Roustit et al. Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence
Wan et al. Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus
BR112012018529A2 (pt) inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
Suhrbier et al. The immunobiology of viral arthritides
Yao et al. H1N1 influenza virus dose dependent induction of dysregulated innate immune responses and STAT1/3 activation are associated with pulmonary immunopathological damage
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
JP2023521887A5 (cg-RX-API-DMAC7.html)
WO2021207399A1 (en) Hydrolysable tannins for use in mitigating acute respiratory distress syndrome
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
Yuexia et al. Combination of ribavirin and reduning protects mice against severe pneumonia induced by H1N1 influenza a virus
CY1115876T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο μιας τριαζολοβενζοδιαζεπινης και ενος εκλεκτικου αναστολεα της επαναπροσληψης σεροτονινης
WO2010003472A3 (de) Lutschzusammensetzung zur behandlung von entzündlichen erkrankungen des mund- und rachenraums
Alihosseini et al. Current drugs with potential for coronavirus disease 2019 therapy: a literature review
CN115803090A (zh) 包含六氧化四砷的用于预防或治疗冠状病毒感染症的药物组合物
JP2018503688A (ja) 感染症を患う被験体における抗感染症療法の期間を短縮する方法
EA201691693A3 (ru) Комбинированный лекарстсвенный препарат в форме шипучих таблеток и способ его получения
BR112016028616A2 (pt) compostos para inibir vírus da hepatite c, composições farmacêuticas e usos dos mesmos
CY1113544T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements